[Neuroleptic therapy in schizophrenia].
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002247:Carbon Isotopes; D002395:Catecholamines / Q000378:metabolism; D002746:Chlorpromazine / Q000627:therapeutic use; D004298:Dopamine / Q000096:biosynthesis / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D051379:Mice; D010648:Phenylacetates / Q000134:cerebrospinal fluid; D010919:Placebos; D012559:Schizophrenia / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000627:therapeutic use*; D014443:Tyrosine / Q000378:metabolism
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D002247:Carbon Isotopes; D002395:Catecholamines; D010648:Phenylacetates; D010919:Placebos; D014149:Tranquilizing Agents; D014443:Tyrosine; D002746:Chlorpromazine; D004298:Dopamine
Neuroleptikabehandling vid schizofreni.